Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
MEREData from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025
August 12, 2025Earnings
Read more →